Graeme Bell, who has more than 20 years of extensive global financial experience within the pharmaceutical industry, will be Anacor Pharmaceuticals Inc.’s new executive vice president and chief financial officer.
Bell took the place of Geoffrey Parker on Monday. Parker will continue working with Anacor as a consultant while the company transitions under its new leadership.
“Graeme is an experienced pharmaceutical executive whose two decades in financial leadership roles at Merck transforming strategic business initiatives into meaningful results will be invaluable to Anacor as we continue our evolution as an emerging commercial pharmaceutical company,” Anacor Chairman and Chief Executive Officer Paul Berns said. “He brings extensive business development, strategic, operational and investor relations experience, practical expertise resourcing product launches, as well as exceptional financial leadership skills. We are excited to add a senior executive of Graeme’s caliber to Anacor and believe he will prove a strong addition to our executive team. In addition, I also want to thank Geoff for his many contributions during his term as chief financial officer and for his commitment to our stockholders, employees and other stakeholders.”
Previously, Bell served as vice president of Merck & Co., where he was responsible for the support and oversight of finances within the company’s U.S. vaccine and pharmaceutical business.
“I am very pleased to join Anacor and its leadership team at such an exciting time,” Bell said. “Anacor’s recently approved product, KERYDIN, Phase 3 asset, AN2728, and innovative product development efforts present a unique and compelling opportunity to create value for patients, healthcare providers and Anacor’s stockholders. I’m keen to begin contributing to Anacor’s success going forward.”